0 items USD 0.00Promising Therapies for B-cell Non-Hodgkin鈥檚 Lymphoma (NHL)
Unmet needs remain in B-cell NHL, which will provide opportunities for developers, including the need for predictive and prognostic biomarkers, better therapies for relapsed or refractory DLBCL, further options in FL for specific patient subsets, and therapies for MCL patients refractory to and relapsed after treatment with Imbruvica.
Leading 麻豆原创ed Therapies for B-cell Non-Hodgkin鈥檚 Lymphoma (NHL)听
CAR-T therapies, including the currently marketed Yescarta and Kymriah and the pipeline agent lisocabtagene maraleucel, are expected to result in significant revenues due to premium pricing and clinical benefit in heavily pre-treated patients. Their combined revenues are expected to reach around USD 2.4bn in 2027.
听
Increasing prevalence, primarily by aging populations and the approval and launch of new branded therapies: lisocabtagene maraleucel, ublituximab with umbralisib, Blincyto, tafasitamab, Venclexta, and enzastaurin will drive market growth. FDA approved currently marketed therapies are:听
- Yescarta
- Kymriah
- Polivy
- Revlimid
- Calquence
- Aliqopa
- Imbruvica
CAR-T therapies have been highly anticipated in NHL, and they are expected to improve treatment outcomes in heavily-treated patients, an area of major unmet need. While currently only approved for the DLBCL subtype, CAR-T therapies are expected to expand into FL, MZL and MCL, and earlier lines of therapy between 2017 and 2027.听
听
听
B-Cell Non-Hodgkin鈥檚 Lymphoma (NHL): Opportunity Analysis and Forecasts to 2027 report offers an overview of B-cell NHL (FL, MZL, DLBCL and MCL), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
It also offers an insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
听
B-cell non-Hodgkin鈥檚 lymphoma (NHL) 麻豆原创 Forecast
The B-cell non-Hodgkin鈥檚 lymphoma (NHL) market is expected to grow from $5.7bn in 2017 to USD 9.2bn by 2027 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 4.9%. The main driver of the growth will be the rise of chimeric antigen receptor (CAR) T cell therapies.
听
The growth of the B-cell NHL market will be tempered by the patent expiry of leading brands, including Rituxan, Treanda, Gazyva, Revlimid, Imbruvica, Zydelig, and Velcade, and subsequent biosimilar/generic erosion. A major barrier for market growth in B-cell NHL, however, will be the increased use of biosimilars and generics, in particular, biosimilar rituximab. The branded Rituxan alone brought in around USD 2.5bn in the US in 2018.
听
Related Reports
B-Cell Non-Hodgkin鈥檚 Lymphoma: Epidemiology Forecast to 2027
B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H2, 2018s
Hodgkin鈥檚 lymphoma (HL) 麻豆原创 Insight, Epidemiology and 麻豆原创 Forecast
Hodgkin鈥檚 lymphoma (HL) -Epidemiology Forecast
Global Non-Hodgkin Lymphoma Therapeutics 麻豆原创 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H2 2018
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2018
听
Browse More Reports from our Database
听
Related Biotech Industry Articles
1.听RNA-Targeted Small Molecules: Emerging Discoveries are Catching the Eye of Investors
2.听Amgen and Roche to Lead Global Bispecific Antibodies 麻豆原创
3.听Top 10 Oncology Pharma Companies in the World
听
Email a colleague
Printer version
Send by email
听
About The Author
Sudeep Chakravarty
